Linical Celebrates 20 Years of Advancing Clinical Research and Patient Wellbeing
OSAKA, Japan , /CNW/ -- Linical, a leader in clinical research services, is proud to celebrate its 20th anniversary — a milestone that reflects two decades of dedication to improving health outcomes through high-quality, patient-centered research. Since its founding in 2005 in Japan , the company has grown from a small team with a bold vision into a global organization supporting clinical trials in more than 30 countries.
From the beginning, Linical set out to do more than manage clinical studies — the company set out to make a meaningful impact on patients' lives. Over the years, Linical's services have expanded to include full-service clinical trial management, site selection and feasibility, regulatory support, biometrics, pharmacovigilance, and drug development strategies. Throughout this growth, Linical's core mission has remained the same: to advance science while prioritizing patient safety and wellbeing.
"What began as a small startup with a few dedicated professionals from the pharmaceutical industry has grown into a global force in clinical research," said Kazuhiro Hatano , President and CEO of Linical. "We've never lost sight of the fact that at the heart of every clinical trial is a patient who is hoping for a better future. That's what continues to drive us."
Over the past two decades, Linical has supported hundreds of clinical studies across a range of therapeutic areas including oncology, neurology, immunology, and rare diseases. By leveraging technology and data-driven processes, the company has delivered faster study start-up times, improved site performance, and enhanced trial quality. Its investments in decentralized trial capabilities and digital tools have positioned the company at the forefront of innovation, especially in an era where flexibility and accessibility in research are more critical than ever.
The company attributes its success to a collaborative culture, strong partnerships with sponsors and sites, and an unwavering focus on patients. "Clinical research is ultimately about people," added Mr. Hatano. "It's about the people participating in trials, the investigators treating them, and the sponsors developing new therapies. We're proud to be part of that ecosystem, helping turn scientific discovery into real-world impact."
As it marks its 20th year, Linical is also looking ahead. The arrival of artificial intelligence is transforming the clinical research industry. With continued investment in global operations, advanced analytics, and patient-focused technologies, the company plans to further strengthen its ability to deliver efficient, high-quality clinical trials that bring new treatments to market faster.
"We're proud of what we've achieved, but we're even more excited about the future," said Mr. Hatano. "Our work is far from done, and we remain committed to our purpose: improving lives through research."
About Linical:
Linical is a global provider of clinical research services, supporting biopharmaceutical companies in bringing innovative therapies to patients across APAC, Europe , and North America . With a focus on quality, technology, and patient wellbeing, Linical delivers tailored solutions for clinical trials across all phases and numerous therapeutic areas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Ovarian Cancer Market Forecast to 2034: Advancing Treatment Frontiers and Epidemiological Shifts
Ovarian cancer remains a significant global health challenge, often diagnosed at an advanced stage due to non-specific symptoms and a lack of effective early screening. It encompasses a spectrum of histological subtypes, including high-grade serous (HGSOC), low-grade serous (LGSOC), and epithelial tumors, each with unique biological and clinical features. High recurrence rates and poor long-term survival continue to drive the urgent need for improved treatment options and earlier detection. DelveInsight's latest report, ' Ovarian Cancer – Market Insight, Epidemiology, and Market Forecast – 2034,' provides a comprehensive overview of the disease's burden across the US, EU4 (Germany, France, Italy, Spain), the UK, and Japan. It offers in-depth segmentation by subtype, stage, age group, and biomarker status, alongside historical and projected epidemiological trends. The analysis highlights rising incidence rates, shifting subtype proportions—particularly serous carcinomas—and the evolving landscape of diagnostic and therapeutic innovation. The ovarian cancer market has transformed in recent years, driven by the expanding use of PARP inhibitors, antiangiogenic agents, and emerging targeted therapies. These options have shifted the treatment paradigm, particularly for BRCA-mutated, HRD-positive, and platinum-sensitive disease. Nonetheless, persistent issues such as chemoresistance, limited options in late-line settings, and variability in biomarker testing are hindering further progress. Looking ahead, the market is anticipated to grow steadily through 2034, propelled by innovations in epigenetic modulators, antibody-drug conjugates (ADCs), immune-oncology combinations, and advanced diagnostics like liquid biopsies. Enhanced biomarker testing and personalized treatment strategies will support optimized patient care. DelveInsight's full report explores pipeline highlights, market drivers and barriers, and strategic recommendations for stakeholders aiming to transform the outlook for ovarian cancer patients. Request a sample and uncover the latest breakthroughs shaping the Ovarian Cancer market landscape and future outlook Some of the key insights of the Ovarian Cancer Market Report: • In 2024, the ovarian cancer market in the 7MM was valued at USD 2.7 billion. • Market size is expected to grow with the launch of new ovarian cancer therapies. • The U.S. held the largest share, reaching USD 1.92 billion in 2024. • Total incident ovarian cancer cases in the 7MM were 61K in 2024. • The U.S. reported the highest number of high and low-grade serous ovarian cancer cases. • There were approximately 37.6K serous ovarian cancer cases in the 7MM in 2024. • In January 2025, IPS HEART received Orphan Drug Designation (ODD) from the FDA for GIVI-MPCs, recognizing their potential to create new muscle with full-length dystrophin in Becker Muscular Dystrophy (BMD). The therapy has shown promising results in generating human muscle with full-length dystrophin in dystrophic pigs, young and aged Duchenne Muscular Dystrophy (DMD) mice, and an Ovarian Cancer mouse model. • In April 2025, Biocon Biologics received FDA approval for JOBEVNE (bevacizumab-nwgd), a biosimilar to Avastin®, for intravenous use. JOBEVNE is approved for multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and ovarian, fallopian tube, or primary peritoneal cancer. • In February 2025, the FDA granted fast-track designation to CUSP06, a CDH6-directed antibody-drug conjugate (ADC), for the treatment of patients with platinum-resistant ovarian cancer. • Emerging therapies for ovarian cancer include Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Key companies involved in the treatment of ovarian cancer include Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. Curious to see the graphical version of these numbers? The ovarian cancer infographic is ready for you. Check it out here! Ovarian Cancer Overview Ovarian cancer is a complex and often late-diagnosed malignancy arising from the epithelial cells, stromal cells, or germ cells of the ovary. Among these, epithelial ovarian cancer is the most prevalent, accounting for over 90% of malignant ovarian tumors. Due to its subtle early symptoms and lack of reliable screening methods, the disease is frequently diagnosed at advanced stages, contributing to its high mortality rate among gynecological cancers. The most common and aggressive subtype is High-Grade Serous Ovarian Cancer (HGSOC), which often presents with widespread peritoneal metastases. In contrast, Low-Grade Serous Ovarian Cancer (LGSOC) tends to follow a more indolent course but shows resistance to standard chemotherapy, highlighting a critical unmet need for targeted therapies. Genetic mutations such as BRCA1/2 and alterations in the MAPK pathway (BRAF/KRAS/NRAS/NF1) and homologous recombination deficiency (HRD) status play a pivotal role in disease stratification and therapy selection. Over the past decade, the ovarian cancer treatment landscape has evolved with the introduction of PARP inhibitors, anti-angiogenic agents, and targeted therapies that have significantly improved outcomes in biomarker-driven subpopulations. Despite these advancements, resistance development, limited options for certain subtypes like LGSOC, and high relapse rates continue to challenge long-term disease control. As research progresses, efforts are focused on improving early diagnosis, personalizing treatment based on molecular profiling, and expanding therapeutic options through clinical trials and novel drug development. Get a free sample for the Ovarian Cancer market forecast, size & share analysis report: Ovarian Cancer Epidemiology The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends. Ovarian Cancer Epidemiology Segmentation: The Ovarian Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: • Total incident cases of Ovarian Cancer • Age-specific cases of Ovarian Cancer • Type-Specific Cases of Ovarian Cancer • Stage-specific Cases of high and Low-Grade Serous Ovarian Cancer • Biomarker-specific Cases of high and Low-Grade Serous Ovarian Cancer Ovarian Cancer Drugs Uptake and Pipeline Development Activities The Drug Uptake section offers a detailed analysis of the adoption trends of newly launched and upcoming therapies for Ovarian Cancer throughout the study period. It evaluates patient adoption rates, market penetration, and the commercial performance of each therapy, providing a clear understanding of the factors driving or hindering the market acceptance of these treatments. The Therapeutics Assessment further highlights the Ovarian Cancer drugs, demonstrating the most rapid uptake. It examines the underlying drivers contributing to their swift adoption and compares the market share of these therapies to identify those gaining significant traction. Additionally, the report provides an in-depth overview of the current therapeutic pipeline for Ovarian Cancer, covering investigational drugs at various stages of development. It profiles the key pharmaceutical and biotech companies actively involved in advancing targeted treatments and presents the latest updates on partnerships, mergers and acquisitions, licensing deals, and other strategic developments shaping the future of Ovarian Cancer therapeutics. Ovarian Cancer Market Outlook The ovarian cancer treatment landscape is undergoing a significant transformation, with the integration of targeted therapies, personalized medicine, and ongoing clinical research aimed at improving long-term outcomes. High-grade serous ovarian cancer (HGSOC), the most prevalent subtype, continues to be treated with a combination of surgery and platinum-based chemotherapy. However, the emergence of maintenance therapies—especially PARP inhibitors—has reshaped post-treatment strategies for patients with BRCA or HRD mutations, helping reduce recurrence rates and extend progression-free survival. The future of ovarian cancer care is increasingly personalized, with clinical trials exploring novel options like immunotherapy, vaccine-based approaches, and radiation strategies for advanced or recurrent disease. These innovations reflect a broader trend toward therapies tailored to molecular profiles and disease stage, moving away from one-size-fits-all treatment. However, disparities in access to care remain a major challenge. Socioeconomic, racial, and geographic barriers often limit timely diagnosis and appropriate treatment, particularly in underserved populations. As awareness of BRCA testing and biomarker-driven treatment grows, expanding access to genetic screening and oncology expertise will be crucial. The ovarian cancer market is expected to expand steadily through 2034, driven by rising disease burden, evolving therapeutic options, and a growing emphasis on precision medicine. Addressing current gaps in care delivery, especially among high-risk and underserved groups, will be essential to unlocking the full potential of these medical advancements. Ovarian Cancer Market Drivers • The introduction of PARP inhibitors (e.g., olaparib, niraparib) and other targeted agents based on BRCA and HRD status has revolutionized ovarian cancer treatment, improving survival and reducing recurrence in select patient groups. • Increasing adoption of genetic and molecular testing for BRCA mutations, HRD status, and other biomarkers is enabling personalized treatment strategies, driving demand for advanced therapeutic options. Ovarian Cancer Market Barriers • The absence of reliable early screening methods and vague initial symptoms often lead to diagnosis at advanced stages, limiting curative treatment options and affecting patient outcomes. • Limited access to specialized oncology care, especially in rural and low-income regions, along with underutilization of genetic testing among minority populations, continues to hinder equitable treatment and diagnosis. Scope of the Ovarian Cancer Market Report • Study Period: 2020–2034 • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]. • Key Ovarian Cancer Companies: Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics, Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and others. • Key Ovarian Cancer Therapies: Avutometinib + defactinib, Relacorilant, IMFINZI, Rinatabart sesutecan, Olvimulogene nanivacirepvec, Nemvaleukin alfa, Catequentinib, Raludotatug deruxtecan, Luveltamab Tazevibulin, Sacituzumab tirumotecan, Azenosertib (ZN-c3) + Niraparib, TORL-1-23, and others. • Ovarian Cancer Therapeutic Assessment: Ovarian Cancer currently marketed, and Ovarian Cancer emerging therapies. • Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers. • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies. • Ovarian Cancer Unmet Needs, KOL's views, Analyst's views, Ovarian Cancer Market Access and Reimbursement. Table of Contents 1. Ovarian Cancer Market Report Introduction 2. Executive Summary for Ovarian Cancer 3. SWOT analysis of Ovarian Cancer 4. Ovarian Cancer Patient Share (%) Overview at a Glance 5. Ovarian Cancer Market Overview at a Glance 6. Ovarian Cancer Disease Background and Overview 7. Ovarian Cancer Epidemiology and Patient Population 8. Country-Specific Patient Population of Ovarian Cancer 9. Ovarian Cancer Current Treatment and Medical Practices 10. Ovarian Cancer Unmet Needs 11. Ovarian Cancer Emerging Therapies 12. Ovarian Cancer Market Outlook 13. Country-Wise Ovarian Cancer Market Analysis (2020–2034) 14. Ovarian Cancer Market Access and Reimbursement of Therapies 15. Ovarian Cancer Market Drivers 16. Ovarian Cancer Market Barriers 17. Ovarian Cancer Appendix 18. Ovarian Cancer Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve. Media Contact Company Name: DelveInsight Contact Person: Jatin Vimal Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
Globe and Mail
3 days ago
- Globe and Mail
Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC
The Key Myasthenia Gravis Companies in the market include - Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others. DelveInsight's 'Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Myasthenia Gravis Market Report: Among the 7MM countries the Myasthenia Gravis market size was valued approximately USD 3,880 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In April 2025, Impressive findings from the Phase 3 clinical trial (NCT05737160) evaluating the safety and effectiveness of Telitacicept (also known as RC18; brand name: 泰爱®) in individuals with generalized myasthenia gravis (gMG) were presented during the Late-Breaking Science Session at the 2025 American Academy of Neurology (AAN) Annual Meeting. In March 2025, Immunovant has opted not to seek regulatory approval for its myasthenia gravis (MG) therapy, batoclimab, even though the Phase III trial achieved its primary goal of reducing disease symptoms. Instead, the company plans to use the trial data to support the advancement of its alternative candidate, IMVT-1402. The Phase III randomized study (NCT05403541) evaluated the effects of weekly or bi-weekly batoclimab dosing in acetylcholine receptor antibody-positive (AChR+) patients, measuring improvements through the Myasthenia Gravis Activities of Daily Living (MG-ADL) score over 12 weeks. In December 2024, Cartesian Therapeutics has shared updated efficacy and safety results from its Phase IIb trial evaluating Descartes-08, an mRNA cell therapy candidate for generalized myasthenia gravis (MG). The findings demonstrated durable responses at 12 months. This open-label, double-blind, placebo-controlled, crossover study (NCT06038474) enrolled 36 symptomatic patients who had previously undergone extensive treatment. Participants were divided evenly, with one group receiving a placebo and the other receiving Descartes-08. Both groups underwent six weekly outpatient infusions, administered without the need for prior chemotherapy-based preconditioning. In October 2024, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune disorders, announced plans to present findings from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). The data will be shared at the 2024 Myasthenia Gravis Foundation of America (MGFA) Scientific Session, held during the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting. The combined myasthenia gravis market size in the European Union's four largest economies and the United Kingdom was approximately USD 950 million in 2023. This figure is expected to increase over the forecast period from 2024 to 2034. In June 2024, Johnson & Johnson (NYSE: JNJ) has announced encouraging outcomes from the Phase 3 Vivacity-MG3 trial of nipocalimab in patients with generalized myasthenia gravis (gMG). The trial demonstrated that patients receiving nipocalimab alongside standard of care (SOC) showed significant improvement in the MG-ADL score over 24 weeks compared to those on placebo plus SOC, meeting the primary endpoint. These findings are part of eight abstracts Johnson & Johnson will present at the 2024 European Academy of Neurology (EAN) Congress. Additionally, the data will be included in regulatory submissions later this year. In January 2024, Johnson & Johnson reported the headline findings from the critical Phase III VIVACITY trial of nipocalimab in adults with generalized myasthenia gravis (gMG). In this Phase III study, nipocalimab met its primary goal, demonstrating a statistically significant decrease in MG-ADL score from baseline during weeks 22 to 24 compared to placebo (PBO). According to DelveInsight's evaluation in 2023, the seven major markets (7MM) had an estimated 297,000 diagnosed prevalent instances of myasthenia gravis, with an expected upward trajectory in these cases anticipated during the forecast period from 2024 to 2034. In 2023, the United States had the largest number of diagnosed prevalent cases of myasthenia gravis among the seven major markets (7MM), totaling approximately 133,000 cases. It is projected that these figures will increase during the forecast period from 2024 to 2034. In 2023, myasthenia gravis affected 48% of males and 52% of females across the seven major markets (7MM). In the United States, there were approximately 66,000 cases among males and around 67,000 cases among females in 2023. These gender-specific incidences are projected to increase during the forecast period from 2024 to 2034. Emerging treatments for myasthenia gravis like Nipocalimab, Batoclimab, Descartes-08, ENSPRYNG (satralizumab), and others hold promise to substantially impact the market size of myasthenia gravis in a positive direction. Key Myasthenia Gravis Companies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others Key Myasthenia Gravis Therapies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others The Myasthenia Gravis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myasthenia Gravis pipeline products will significantly revolutionize the Myasthenia Gravis market dynamics. Myasthenia Gravis Overview Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by weakness and fatigue of voluntary muscles. It occurs when the body's immune system mistakenly attacks and damages the communication between nerve cells and muscles, specifically at the neuromuscular junction. Myasthenia Gravis Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Myasthenia Gravis Epidemiology Segmentation: The Myasthenia Gravis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalence of Myasthenia Gravis Prevalent Cases of Myasthenia Gravis by severity Gender-specific Prevalence of Myasthenia Gravis Diagnosed Cases of Episodic and Chronic Myasthenia Gravis Download the report to understand which factors are driving Myasthenia Gravis epidemiology trends @ Myasthenia Gravis Epidemiology Forecast Myasthenia Gravis Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myasthenia Gravis market or expected to get launched during the study period. The analysis covers Myasthenia Gravis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Myasthenia Gravis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Myasthenia Gravis Therapies and Key Companies Myasthenia Gravis Market Strengths The growing prevalence of myasthenia gravis (MG) and the geriatric population offers a stable market demand for treatments and therapies. Myasthenia gravis treatments may qualify for orphan drug status, offering regulatory incentives, such as extended market exclusivity and tax benefits. Myasthenia Gravis Market Opportunities Potential for developing new, more effective therapies, such as gene therapy or targeted biologics, could address unmet medical needs. Improved diagnostic techniques using clear biomarkers and an increase in awareness will likely lead to a diagnosis of more patients, expanding the market. Scope of the Myasthenia Gravis Market Report Study Period: 2020-2034 Coverage: 7MM Countries Key Myasthenia Gravis Companies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others Key Myasthenia Gravis Therapies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Myasthenia Gravis Unmet Needs, KOL's views, Analyst's views, Myasthenia Gravis Market Access and Reimbursement Table of Contents 1. Myasthenia Gravis Market Report Introduction 2. Executive Summary for Myasthenia Gravis 3. SWOT analysis of Myasthenia Gravis 4. Myasthenia Gravis Patient Share (%) Overview at a Glance 5. Myasthenia Gravis Market Overview at a Glance 6. Myasthenia Gravis Disease Background and Overview 7. Myasthenia Gravis Epidemiology and Patient Population 8. Country-Specific Patient Population of Myasthenia Gravis 9. Myasthenia Gravis Current Treatment and Medical Practices 10. Myasthenia Gravis Unmet Needs 11. Myasthenia Gravis Emerging Therapies 12. Myasthenia Gravis Market Outlook 13. Country-Wise Myasthenia Gravis Market Analysis (2020-2034) 14. Myasthenia Gravis Market Access and Reimbursement of Therapies 15. Myasthenia Gravis Market Drivers 16. Myasthenia Gravis Market Barriers 17. Myasthenia Gravis Appendix 18. Myasthenia Gravis Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
3 days ago
- Globe and Mail
Participation in 'The 113th Congress of Japan Society of Aesthetic Surgery,' May 2025
IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ('SBC Medical') today announced that a total of 22 representatives, including Yoshiyuki Aikawa, CEO of SBC Medical, and doctors from Shonan Beauty Clinic, a clinic operated under the management support of SBC Medical Group, a consolidated subsidiary, presented their research findings at 'The 113th Congress of Japan Society of Aesthetic Surgery.' Yoshiyuki Aikawa, CEO of SBC Medical Group Holdings Incorporated The Japan Society of Aesthetic Surgery (JSAS), one of Japan's leading professional societies in the field of aesthetic medicine, brings together doctors dedicated to shaping the future of the industry. 'The 113th Congress of Japan Society of Aesthetic Surgery' was held over three days from Wednesday, May 28 to Friday, May 30, 2025, at The Okura Tokyo. Under the theme 'TO BE THE BEST -The Journey of Knowledge Never Ends-,' the congress was chaired in part by Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, who served as Vice Chair of the event. The congress provided a valuable platform for in-depth discussions on international trends and future developments in aesthetic medicine, fostering both academic and clinical insights and promoting global collaboration among experts in the field. Dr. Ayaka Nishikawa, Director of Dermatology Department of Shonan Beauty Group, served as Vice Chair of this Congress At this congress, a total of 22 representatives from SBC Medical presented their research findings, including Yoshiyuki Aikawa, CEO of SBC Medical, Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group, Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group and Dr. Ayaka Nishikawa, who also served as Vice Chair of the congress. Each speaker shared insights cultivated through daily clinical practice and research in their respective fields of expertise. The event also featured lively discussions on global trends and future developments in aesthetic medicine, providing a valuable opportunity to deepen academic and clinical knowledge and to foster international collaboration. Dr. Daisuke Nakamura, Chief Medical Director of Shonan Beauty Group Dr. Kazuhiro Igawa, Representative Assistant of Shonan Beauty Group In the rapidly evolving field of aesthetic medicine, the importance of both acquiring and sharing specialized knowledge continues to grow. As technological advancements drive increasingly diverse customer needs, it is essential not only to adopt cutting-edge technologies, but also to maintain a broad and multifaceted perspective. SBC Medical remains committed to contributing to the advancement of the aesthetic medicine industry by actively engaging with academic societies and research institutions, sharing our innovative initiatives, and incorporating the latest global knowledge and technologies into our practice. The 113th Congress of Japan Society of Aesthetic Surgery Venue：The Okura Tokyo Dates：Wednesday, May 28 – Friday, May 30, 2025 Official website： Presentation Topics Chair / Speaker Job Title Title Yoshiyuki Aikawa CEO, SBC Medical Group Holdings 【Special Program/Speaker】 Practical Strategies for Cosmetic Medical Business Management and Marketing 【Special Lecture/Chair】The future of cosmetic medicine and AI Daisuke Nakamura Chief Medical Director of Shonan Beauty Group, Chief of Breast Augmentation at SBC 【Symposium/Speaker】Creating an attractive bust line - Fat injection breast augmentation and breast implant augmentation Kazuhiro Igawa Representative Assistant and Technical Advisor, Shonan Beauty Group 【Symposium/Speaker】Rhinoplasty with an awareness of harmony by considering facial parts as fonts Ayaka Nishikawa Director of Dermatology Department of Shonan Beauty Group 【Luncheon Seminar/Chair/Speaker】The Potential of Microneedle RF：Indications and Practical Combination Treatments in Skin Management 【Invited Lecture/Chair】Unique Treatments and Techniques with injectable Agents A 35 Year Evolution 【Symposium/Speaker】Challenges in Skin Tightening Devices: Insights from Single-Device Treatments with 6.78MHz Monopolar RF 【Sponsored Seminar/Chair】'The WHY'? -Why do we do what we do as an aesthetics injector? 【Presidential Special Program/Speaker】Evaluating the Impact of Different Approaches in Aesthetic Dermatology: A Post-Treatment Study in Identical Twins 【Sponsored Seminar/Speaker】Fine fiber sheet for application after pico-second laser treatment Jiro Kataoka Area Medical Director and Anti-Aging Expert Doctor 【Panel Discussion/Speaker】Deep Plane Facelift for Japanese (Asians) ~My Experience and Ideas~ 【Video Lecture/Chair】Fundamentals and applications of Facelift Surgery: Strategies for Addressing Age-Related Changes Shoko Takahashi Top expert doctor in rejuvenation 【Panel Discussion/Speaker】Patient education and combination treatment to maximize patient satisfaction with thread lifting Hiroaki Takizawa Area Doctor and Director of Jiyugaoka Clinic 【Symposium/Speaker】Revision after double eyelid surgery with sub-brow blepharoplasty Eiko Tanaka Director of Takatsuki Hospital 【Symposium/Chair/Speaker】Innovative Approaches to Improve Labia Majora Laxity: Minimizing Scars in Reduction Surgery Atsushi Hayashi Chief Technical Director 【Panel Discussion/Speaker】Incidence of Post-inflammatory Hyperpigmentation with Picosecond Laser in Patients with Melasma Kanako Misono Slimming Expert Doctor 【Luncheon Seminar/Speaker】Cutting edge of Cryolipolysis: Maximize patient satisfaction with Coolsculpting Soichiro Morikawa Anti-aging treatment expert doctor 【Luncheon Seminar/Speaker】Polynucleotide products and Hyaluronic Acid Filler Poster Presentations Speaker Job Title Title Hiroshi Ohji ー Usefulness of preoperative ultrasound examination in submandibular liposuction. Ayano Okuda Expert doctor in gynecological plastic surgery Diversifying Intimate Area Treatments ~Changes and Current Status of Pubic Hair Removal and Female Genital plastic surgery at Our Clinic~ Go Kanazawa Director of Hiroshima Clinic and Area Doctor for Hiroshima Area Lessons learned from the experience of removing limps formed by fat injection into the lower eyelid Kaito Kuzushima Ginza Clinic Director Top Expert Doctor in Liposuction Asian Buttocks Contouring：witout fat injection 【Evaluated with 3D Vectra】 Aiko Ssasaki Kawagoe Area Area Doctor and Director of Kawagoe Clinic Comparison of eyelid functions before and after completely transconjunctival embedding double eyelid blepharoplasty Yuka Takeda Director of the Esaka Institute The usefulness of next generation needle Nanosoft Microneedles Lifting Effects and Technical Innovations in Full-Face Autologous Fat Grafting Ryuji Tanaka Hokkaido/Tohoku Area General Manager Approach to the Management of Lower Eyelid Hollowness with Skin Laxity Mei Nakayama ー Bilateral symmetrical enlargement within a few months after upper arm liposuction : case report Ayaka Nishikawa Director of Dermatology Department of Shonan Beauty Group Fine fiber sheet for application after pico-second laser treatment Yu Hirata Director of Okayama Clinic and Area Doctor for Okayama Area Study on the direction of fat repositioning in transconjunctival blepharoplasty. Takashi Yamamoto Director of Nagoya Institute Examination of the effects, satisfaction, and risks of orbital fat removal combined with the buried double method Akihiro Yoshida ー Tips to improve the success rate of transconjunctival double eyelid blepharoplasty suture removal About SBC Medical SBC Medical, headquartered in Irvine, California and Tokyo, Japan, owns and provides management services and products to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including but not limited to advertising and marketing needs across various platforms (such as social media networks), staff management (such as recruitment and training), booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumables procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic's customer rewards program (customer loyalty point program), and payment tools for the franchisee clinics. For more information, visit Contacts In Asia: SBC Medical Group Holdings Incorporated Hikaru Fukui / Head of Investor Relations E-mail: ir@ In the US: ICR LLC Bill Zima / Managing Partner Email:
